Gapping up
In reaction to strong earnings/guidance: AU +8.6%
M&A news: MARA +6.2% (Marathon Patent Group and Uniloc Luxembourg SA to combine in an all-stock merger of equals, new company will be called Marathon Group SA )
Select Israel related names showing strength: CEL +10.3%, PTNR +7%, ALLT +2%, TSEM +1.5%, CAMT +1.4%
Select metals/mining stocks trading higher: DRD +7.1%, GFI +3.8%, HMY +1.9%, GG +1.8%, ABX +1.2%, GDX +0.8%
Other news: AVEO +118.8% (AVEO Oncology and Novartis (NVS) announce an exclusive, worldwide license agreement to develop and commercialize Aveo's GDF15 and AV-380 ), OHRP +17% (disclosure of purchase of 12.1k shares in 13F filing by Soros Fund), BLRX +4.6% (initiation of Phase 2b Trial for novel AML consolidation treatment), OMER +4.2% (announces plan to file a patent infringement lawsuit against Par Pharmaceutical), CRNT +3.6% (cont volatility in pre-mkt), MNKD +2.7% (cont volatility in pre-mkt), MBLY +2.3% (Jana Partners increases position in co according to 13F filing), PSTI +1.8% (receives patent for production methods and use of placental cell therapy), SUNE +1.7% (Greenlight Capital increased pos size according to 13F), CHMA +1.6% (FDA has accepted for filing the Company's New Drug Application for the marketing and sale of octreotide capsules)
Analyst comments: TSLA +5.3% (target raised to $465 from $280 at Morgan Stanley), JCP +2.6% (initiated with a Buy at B. Riley & Co), ZUMZ +2.2% (upgraded to Positive from Neutral at Susquehanna), BXLT +1.5% (initiated with an Outperform at William Blair), OAS +1.4% (upgraded to Outperform at BMO Capital), JPM +0.7% (upgraded to Outperform from Mkt Perform at Keefe Bruyette
)
In reaction to strong earnings/guidance: AU +8.6%
M&A news: MARA +6.2% (Marathon Patent Group and Uniloc Luxembourg SA to combine in an all-stock merger of equals, new company will be called Marathon Group SA )
Select Israel related names showing strength: CEL +10.3%, PTNR +7%, ALLT +2%, TSEM +1.5%, CAMT +1.4%
Select metals/mining stocks trading higher: DRD +7.1%, GFI +3.8%, HMY +1.9%, GG +1.8%, ABX +1.2%, GDX +0.8%
Other news: AVEO +118.8% (AVEO Oncology and Novartis (NVS) announce an exclusive, worldwide license agreement to develop and commercialize Aveo's GDF15 and AV-380 ), OHRP +17% (disclosure of purchase of 12.1k shares in 13F filing by Soros Fund), BLRX +4.6% (initiation of Phase 2b Trial for novel AML consolidation treatment), OMER +4.2% (announces plan to file a patent infringement lawsuit against Par Pharmaceutical), CRNT +3.6% (cont volatility in pre-mkt), MNKD +2.7% (cont volatility in pre-mkt), MBLY +2.3% (Jana Partners increases position in co according to 13F filing), PSTI +1.8% (receives patent for production methods and use of placental cell therapy), SUNE +1.7% (Greenlight Capital increased pos size according to 13F), CHMA +1.6% (FDA has accepted for filing the Company's New Drug Application for the marketing and sale of octreotide capsules)
Analyst comments: TSLA +5.3% (target raised to $465 from $280 at Morgan Stanley), JCP +2.6% (initiated with a Buy at B. Riley & Co), ZUMZ +2.2% (upgraded to Positive from Neutral at Susquehanna), BXLT +1.5% (initiated with an Outperform at William Blair), OAS +1.4% (upgraded to Outperform at BMO Capital), JPM +0.7% (upgraded to Outperform from Mkt Perform at Keefe Bruyette
)